Recently at the 2018 ASCO-SIC Clinical immune-oncology symposium (CA, USA, 25-27 January) a panel discussed…
Browsing: immune response
Researchers at The institute of Cancer Research (London, UK) have identified six genetic changes that increase the risk of developing Hodgkin lymphoma.
Researchers at the Ludwig Institute for Cancer Research (Brussels, Belgium) have discovered a novel mechanism used by tumors to evade immunotherapies.
Nivolumab has been given the green light for nivolumab for head and neck cancer via the Cancer Drug Fund.
PROGRAM OVERVIEW This case-based enduring activity will cover the treatment and management of patients with…
In a first of its kind study, blood sample analysis detects genomic alterations that can predict which cancer patients should receive checkpoint inhibitor immunotherapy.
Research into the PD-L1 pathway has discovered a novel protein known as CMTM6, which binds to PD-L1 on T cell surfaces and enhances PD-L1’s ability to inhibit T cell immune responses. The findings may offer a novel immunotherapy target for many types of cancer.
A novel CRISPR-Cas9 screening method has revealed new drug targets that could potentially enhance the effectiveness of PD-1 checkpoint inhibitors, a promising class of cancer immunotherapeutics.
Researchers at the University of Pittsburgh (PA, USA) have discovered that targeting regulatory T-cells could be an effective approach to treating cancers.
Possible damage to immune-privileged sites in natural killer cell therapy in cancer patients: side effects of natural killer cell therapy
Find out in this perspective article how cytotoxic and expanded NK cells induced in cancer patients may be turned into pathogenic factors if they enter immune-privileged microenvironments in susceptible individuals.